Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 6, 2015, Pages 619-626

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Diabetes; Epidemiology; Metformin; Ovarian cancer; Taiwan

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER INCIDENCE; CONTROLLED STUDY; DEPENDENT VARIABLE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NATIONAL HEALTH INSURANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REIMBURSEMENT; TAIWANESE; AGED; COHORT ANALYSIS; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; ELECTRONIC HEALTH RECORD; INCIDENCE; NATIONAL HEALTH SERVICE; OVARIAN NEOPLASMS; PRESCRIPTION; RISK FACTOR; TAIWAN;

ADULT; AGED; ANTICARCINOGENIC AGENTS; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PRESCRIPTIONS; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; METFORMIN; MIDDLE AGED; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STATE MEDICINE; SULFONYLUREA COMPOUNDS; TAIWAN;

EID: 84941259525     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2649     Document Type: Article

References (33)

1. Rooth C. Ovarian cancer: risk factors, treatment and management. Br J Nurs 2013; 22: S23-30.
2. Lowe KA, Chia VM, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 2013; 130: 107-114.
3. Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8: e71583.
4. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 2011; 123: 200-204.
5. Baur DM, Klotsche J, Hamnvik OP, et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 2011; 60: 1363-1371.
6. Home PD, Kahn SE, Jones NP, et al.. ADOPT Study Group; RECORD Steering Committee. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010; 53: 1838-1845.
7. Dilokthornsakul P, Chaiyakunapruk N, Termrungruanglert W, et al. The effects of metformin on ovarian cancer: a systematic review. Int J Gynecol Cancer 2013; 23: 1544-1551.
8. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
9. Gerhard T. Bias: considerations for research practice. Am J Health Syst Pharm 2008; 65: 2159-2168.
10. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010; 340: b5087.
11. Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010; 25: 245-251.
12. Yang X, So WY, Ma RC, et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2010; 90: 343-351.
13. Tseng CH. Human insulin does not increase bladder cancer risk. PLoS One 2014; 9: e86517.
14. Tseng CH. Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes. Ann Med 2013; 45: 539-544.
15. Tseng CH. Pioglitazone does not affect the risk of ovarian cancer: analysis of a nationwide reimbursement database in Taiwan. Gynecol Oncol 2013; 131: 135-139.
16. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012; 35: 278-280.
17. Tseng CH. Diabetes is not an independent risk factor for hepatocellular carcinoma. Diabetes Metab Res Rev 2013; 29: 515-524.
18. Weberpals JI, Clark-Knowles KV, Vanderhyden BC. Sporadic epithelial ovarian cancer: clinical relevance of BCRA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 2008; 26: 3259-3267.
19. Ma X, Beeghly-Fadiel A, Shu XO, et al. Anthropometric measures and epithelial ovarian cancer risk among Chinese women: results from the Shanghai Women's Health Study. Br J Cancer 2013; 109: 751-755.
20. Kato K, Gong J, Iwama H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012; 11: 549-560.
21. Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 2011; 15: 166-178.
22. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008; 110: 246-250.
23. Yasmeen A, Beauchamp MC, Piura E, et al. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol 2011; 121: 492-498.
24. Shank JJ, Yang K, Ghannam J, et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 2012; 127: 390-397.
25. Yasukagawa T, Niwa Y, Simizu S, Umezawa K. Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells. FEBS Lett 2012; 586: 1504-1509.
26. El-Deeb IM, Bayoumi SM, El-Sherbeny MA, Abdel-Aziz AA. Synthesis and antitumor evaluation of novel cyclic arylsulfonylureas: ADME-T and pharmacophore prediction. Eur J Med Chem 2010; 45: 2516-2530.
27. Taylor CW, Alberts DS, Peng YM, et al. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer. J Natl Cancer Inst 1992; 84: 1798-1802.
28. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-169.
29. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005; 14: 98-107.
30. Lukanova A, Lundin E, Micheli A, et al. Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy). Cancer Causes Control 2003; 14: 285-292.
31. Ose J, Fortner RT, Schock H, et al. Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. Br J Cancer 2015; 112: 162-166.
32. Schock H, Fortner RT, Surcel HM, et al. Early pregnancy IGF-I and placental GH and risk of epithelial ovarian cancer: a nested case-control study. Int J Cancer 2014 Dec 8. DOI: 10.1002/ijc.29387. [Epub ahead of print]
33. Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumour Biol 2014; 35: 3125-3132.